A kinase-inactive type II TGFβ receptor impairs BMP signaling in human breast cancer cells

Nancy Dumont, Carlos L. Arteaga

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Dominant negative receptor mutants are often utilized in order to abrogate signaling induced by growth factors. We have previously shown that expression of a dominant negative type II TGFβ receptor (dnTβRII) in MDA-MB-231 breast cancer cells effectively abrogates TGFβ signaling. In this letter, we report that expression of dnTβRII also impairs BMP2-mediated Smad1 phosphorylation as well as BMP2-mediated Smad-dependent transcriptional responses, resulting in an attenuation of BMP-mediated anti-proliferative effects. The fact that dnTβRII not only abrogates TGFβ signaling but BMP signaling as well has important implications for the interpretation of data in which dominant negative mutants are utilized.

Original languageEnglish (US)
Pages (from-to)108-112
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume301
Issue number1
DOIs
StatePublished - Jan 31 2003

Keywords

  • Bone morphogenetic protein
  • Dominant negative type II TGFβ receptor
  • Signaling, MDA-MB-231
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'A kinase-inactive type II TGFβ receptor impairs BMP signaling in human breast cancer cells'. Together they form a unique fingerprint.

  • Cite this